Pharmacological activation of wild-type p53 in the therapy of leukemia Kensuke Kojima, Jo Ishizawa, Michael Andreeff  Experimental Hematology  Volume 44, Issue 9, Pages 791-798 (September 2016) DOI: 10.1016/j.exphem.2016.05.014 Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 1 Impaired p53 response in leukemia. p53 transcriptional activity is suppressed by p53-regulatory proteins upstream of p53. Red ovals indicate overexpressed or activated proteins and blue ovals indicate inactivated proteins in leukemia. Experimental Hematology 2016 44, 791-798DOI: (10.1016/j.exphem.2016.05.014) Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 2 Negative correlation of MDM2 and p53 in AML. Three-dimensional surface plot of p53 against MDM2 and XPO1 in 511 patient-derived AML samples is shown [48]. High levels of MDM2 are associated with low levels of p53, implying a pathological role of MDM2 in suppressing p53 function in AML. There is a significant relationship (p = 0.0002) among p53, MDM2, and XPO1, raising the possibility that the p53 nuclear exporter XPO1 also regulates p53 in AML. The color scale refers to the expression (on the log2 scale, as for the rest of the data) of the z-axis component (i.e., p53). Experimental Hematology 2016 44, 791-798DOI: (10.1016/j.exphem.2016.05.014) Copyright © 2016 ISEH - International Society for Experimental Hematology Terms and Conditions